Johnson & Johnson Robotics and Digital Solutions
VC Fund
New Brunswick, United States
Johnson & Johnson Robotics and Digital Solutions is a VC fund in New Brunswick focused on Biotechnology and Health Care. Johnson & Johnson Innovation is a center for science and business experts to collaborate with innovators to incorporate science into healthcare solutions, including medical device and diagnostic technologies, consumer healthcare products, and pharmaceuticals. It is focused on the advancement of new healthcare solutions in the consumer,pharmaceutical, and medical devices and diagnostics sectors.’The company provides financing tools that include early-stage research funding, seed funding, equity investments, licensing, and collaborations. Additionally, it offers its partners access to international markets, pricing and reimbursement, market testing, company creation services, and more. They conduct their activities with the help of regional incubators, satellite operations, single bench tops, modular labs, office space for entrepreneurs, and a year-round curriculum focused on business and drug development.Johnson & Johnson Innovation is a subsidiary of
- Total investments:
- 78
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Johnson & Johnson Robotics and Digital Solutions invests in
Stages Johnson & Johnson Robotics and Digital Solutions invests in
Countries Johnson & Johnson Robotics and Digital Solutions invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $5.9M–$63M
- Series B
- $18M–$55M
- Series C
- $300k–$100M
Investment Focus
Industry
- Biotechnology 50 (64%)
- Health Care 44 (56%)
- Medical 22 (28%)
- Therapeutics 21 (27%)
- Medical Device 16 (21%)
Stage
- Series A 30 (38%)
- Series B 14 (18%)
- Series C 9 (12%)
- Grant 7 (9%)
- Funding Round 4 (5%)
Country
- United States 44 (56%)
- Israel 6 (8%)
- United Kingdom 5 (6%)
- Canada 2 (3%)
- Switzerland 2 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anjali Kumar
External Innovation Search & Evaluation
|
External Innovation Search & Evaluation | Total investments: 0 | Find email | |
Bruce Rosengard
Vice President
|
Vice President | Total investments: 0 | Find email | |
Chris Picariello
President
|
President | Total investments: 1 | Find email | |
James J. Bergin
Vice President, Law
|
Vice President, Law | Total investments: 0 | Find email | |
|
John Magnasco
VP, Quality & Compliance, Robotics & Digital Solutions
|
VP, Quality & Compliance, Robotics & Digital Solutions | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Moon Surgical
|
MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room. | $55.4M / Series B / May 17, 2023 | |
Manus Neurodynamica
|
Manus Neurodynamica is a triage device to support early diagnostics in Parkinson's disease. | Grant / Apr 17, 2023 | |
Glyphic Biotechnologies
|
We sequence proteins. Glyphic Biotechnologies is a biotechnology startup revolutionizing the field of proteomics. While DNA can reveal biological insights, proteins actually tell us what our bodies will do. We are developing a first-of-its-kind, next-generation protein sequencing platform to enable researchers to gain novel insights into biologyand disease. | $100K / Grant / Apr 03, 2023 | |
Artera
|
Artera is a provider of precision medicine and develops artificial intelligence (AI) testing to customize treatments for cancer patients. It develops specialized tools to support personalized clinical care. Its test predicts therapeutic benefits and provides risk stratification. | $90M / Mar 21, 2023 | |
ONL Therapeutics
|
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. The current market for retinal drugs is greater than $7 billion and rapidly growing. Existing therapies have significant limitations and none address the initial neural component of vision loss - the death of the photoreceptorcell. | $15M / Series C / Mar 08, 2023 | |
AmacaThera
|
AmacaThera is a clinical-stage company based in Toronto. AmacaThera is redefining how therapeutics are delivered. AmacaThera has developed a platform hydrogel technology that addresses the critical problem of sustaining therapeutic delivery of pharmacological agents for multiple disease areas. AmacaThera’s lead product addresses post-operative painand consequently may have an impact on the opioid crisis. | Grant / Jan 04, 2023 | |
MedCrypt
|
MedCrypt is a medical device company that provides data security as a service to medical device OEMs. From medical imaging device to implantable devices like pacemakers, MedCrypt ensures that devices act only on instructions from trusted sources. It brings security features to medical devices, from pacemakers to surgical robots, in a few lines ofcode. The company enables engineers to implement these security features properly as quickly as possible, allowing them to get back to designing life-changing clinical features.MedCrypt was founded in 2016 and is headquartered in Encinitas, California, United States. | $25M / Series B / Nov 01, 2022 | |
Nucleome Therapeutics
|
Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 95% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. We have the unique ability to link these variants to genefunction and map disease pathways. Our cell type-specific platform creates high resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types. This enables us to discover and develop novel, better and safer drugs. The initial focus of the company is on lymphocytes and related autoimmune disease. Our ambition is to build a robust pipeline of drug assets, with corresponding biomarkers. Nucleome Therapeutics was founded by leading experts in gene regulation from the University of Oxford and backed by investment from Oxford Sciences Innovation. For more information, please visit www.nucleome.com. | $42M / Series A / Oct 19, 2022 | |
Prana Thoracic
|
Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for early intervention in lung cancer. We are an experienced team of surgeons, engineers and entrepreneurs on a mission to tackle lung cancer; the #1 cancer killer in the US.The paradigm of screening, detection, and early intervention that has beendeployed in other major cancers has so far eluded lung cancer. As a result, only 16% of lung cancers are found at an early stage and the current 5-year survival rate is < 20%. Recent changes to lung cancer screening guidelines have illuminated a path to improving outcomes in lung cancer. However, these advances rely on excising suspicious nodules and providing sufficient tissue for definitive diagnosis. We believe this is the missing piece of the puzzle, and physicians need a new generation of surgical oncology tools for lung cancer.Prana Thoracic plans to revolutionize the early diagnosis and treatment of lung cancer by making it easier and less invasive to deal with the rapidly growing number of early suspicious lung nodules; ensuring that we do not miss the window of opportunity to intervene early. | $3M / Series A / Oct 19, 2022 | |
Cara Care
|
Cara Care is a digital therapeutics company that empowers patients suffering from chronic digestive diseases to enjoy a better life. Cara Care takes digestive health beyond the pill, bringing together behavioral, microbial and nutritional data. Cara Care has already helped 700.000+ patients around the world with software-based medical devices. | $7M / Series A / Jun 13, 2022 | |
| See all 78 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Johnson & Johnson Robotics and Digital Solutions invest in?
Johnson & Johnson Robotics and Digital Solutions invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 78 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Johnson & Johnson Robotics and Digital Solutions's check size?
Johnson & Johnson Robotics and Digital Solutions typically joins rounds of $5.9M–$63M at Series A, $18M–$55M at Series B and $300k–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Johnson & Johnson Robotics and Digital Solutions participates in.
How do I contact Johnson & Johnson Robotics and Digital Solutions?
Public channels for Johnson & Johnson Robotics and Digital Solutions include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Johnson & Johnson Robotics and Digital Solutions?
The team at Johnson & Johnson Robotics and Digital Solutions includes Anjali Kumar (External Innovation Search & Evaluation), Bruce Rosengard (Vice President) and Chris Picariello (President), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
